HilleVax, Inc. (NASDAQ:HLVX) Short Interest Update

HilleVax, Inc. (NASDAQ:HLVX) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 635,100 shares, a growth of 7.6% from the August 15th total of 590,200 shares. Approximately 4.8% of the company’s shares are short sold. Based on an average trading volume of 71,900 shares, the short-interest ratio is currently 8.8 days.

HilleVax Stock Down 4.2 %

NASDAQ HLVX traded down $0.61 on Tuesday, reaching $14.07. The stock had a trading volume of 2,196 shares, compared to its average volume of 63,195. The company has a quick ratio of 13.80, a current ratio of 13.80 and a debt-to-equity ratio of 0.11. HilleVax has a 12-month low of $11.35 and a 12-month high of $23.10. The stock has a fifty day moving average price of $13.94 and a two-hundred day moving average price of $15.05.

HilleVax (NASDAQ:HLVX) last announced its earnings results on Monday, August 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.11. On average, equities research analysts predict that HilleVax will post -3.3 earnings per share for the current year.

Institutional Trading of HilleVax

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. American International Group Inc. purchased a new stake in HilleVax in the second quarter valued at approximately $66,000. Gyon Technologies Capital Management LP purchased a new stake in shares of HilleVax during the fourth quarter worth $53,000. Tower Research Capital LLC TRC increased its position in shares of HilleVax by 57.4% during the first quarter. Tower Research Capital LLC TRC now owns 2,587 shares of the company’s stock worth $43,000 after acquiring an additional 943 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of HilleVax by 80.3% during the second quarter. Ameritas Investment Partners Inc. now owns 1,753 shares of the company’s stock worth $30,000 after acquiring an additional 781 shares during the period. Finally, UBS Group AG increased its position in shares of HilleVax by 9,300.0% during the fourth quarter. UBS Group AG now owns 1,692 shares of the company’s stock worth $28,000 after acquiring an additional 1,674 shares during the period. Hedge funds and other institutional investors own 89.77% of the company’s stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.